Medical Industry Feature

Guest: Scott Gottlieb, MD Host: Charles Turck, PharmD, BCPS, BCCCP Patients 50+ with moderate-to-severe plaque psoriasis face adherence challenges, increased risk of comorbidities, and insurance transitions from commercial to Medicare. To learn more about how ILUMYA® (tildrakizumab-asmn) helps address the specific treatment needs of these patients, join Dr. Charles Turck as he speaks with Dr. Scott Gottlieb, a physician at Schweiger Dermatology Group in Exton, Pennsylvania.